Lv4
790 积分 2023-08-01 加入
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
28天前
已完结
Learning from clinical trials of neoadjuvant checkpoint blockade
28天前
已完结
Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
1个月前
已完结
Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis
1个月前
已完结
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
2个月前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
2个月前
已完结
Unlocking the potential of antibody–drug conjugates for cancer therapy
2个月前
已完结
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer
2个月前
已完结
Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
3个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
6个月前
已完结
皖公网安备34019202002308
